TUG-891

Last updated

TUG-891
TUG-891 structure.png
Identifiers
  • 3-[4-[[5-fluoro-2-(4-methylphenyl)phenyl]methoxy]phenyl]propanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
Formula C23H21FO3
Molar mass 364.416 g·mol−1
3D model (JSmol)
  • CC1=CC=C(C=C1)C2=C(C=C(C=C2)F)COC3=CC=C(C=C3)CCC(=O)O
  • InChI=1S/C23H21FO3/c1-16-2-7-18(8-3-16)22-12-9-20(24)14-19(22)15-27-21-10-4-17(5-11-21)6-13-23(25)26/h2-5,7-12,14H,6,13,15H2,1H3,(H,25,26)
  • Key:LPGBXHWIQNZEJB-UHFFFAOYSA-N

TUG-891 is an experimental drug which acts as a potent and selective agonist for the free fatty acid receptor FFAR4 (GPR120). It has antiinflammatory effects and regulates metabolism, gastric peptide release and glucose homeostasis, and has been researched in animal models of conditions such as obesity, diabetes and atherosclerosis, as well as cancer. [1] [2] [3] [4] [5] [6] [7] [8] [9] TUG-891 was one of the first selective FFAR4 agonists developed and while it is useful for in vitro research, it has poor stability in vivo, and so numerous compounds have been developed with improved properties using TUG-891 as the parent compound. [10] [11] [12] [13] [14]

References

  1. ↑ Hudson BD, Shimpukade B, Mackenzie AE, Butcher AJ, Pediani JD, Christiansen E, et al. (November 2013). "The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism". Molecular Pharmacology. 84 (5): 710–725. doi:10.1124/mol.113.087783. PMC   3807074 . PMID   23979972.
  2. ↑ Cornall LM, Mathai ML, Hryciw DH, McAinch AJ (May 2014). "GPR120 agonism as a countermeasure against metabolic diseases". Drug Discovery Today. 19 (5): 670–679. doi:10.1016/j.drudis.2013.11.021. PMID   24315954.
  3. ↑ Hansen SV, Ulven T (2016). "Pharmacological Tool Compounds for the Free Fatty Acid Receptor 4 (FFA4/GPR120)". Handbook of Experimental Pharmacology. 236: 33–56. doi:10.1007/164_2016_60. ISBN   978-3-319-50692-0. PMID   27807695.
  4. ↑ Schilperoort M, van Dam AD, Hoeke G, Shabalina IG, Okolo A, Hanyaloglu AC, et al. (March 2018). "The GPR120 agonist TUG-891 promotes metabolic health by stimulating mitochondrial respiration in brown fat". EMBO Molecular Medicine. 10 (3). doi:10.15252/emmm.201708047. PMC   5840546 . PMID   29343498.
  5. ↑ Senatorov IS, Moniri NH (April 2018). "The role of free-fatty acid receptor-4 (FFA4) in human cancers and cancer cell lines". Biochemical Pharmacology. 150: 170–180. doi:10.1016/j.bcp.2018.02.011. PMC   5866782 . PMID   29452095.
  6. ↑ Murtaza B, Hichami A, Khan AS, Shimpukade B, Ulven T, Ozdener MH, et al. (February 2020). "Novel GPR120 agonist TUG891 modulates fat taste perception and preference and activates tongue-brain-gut axis in mice". Journal of Lipid Research. 61 (2): 133–142. doi: 10.1194/jlr.RA119000142 . PMC   6997603 . PMID   31806728.
  7. ↑ Christian M (August 2020). "Elucidation of the roles of brown and brite fat genes: GPR120 is a modulator of brown adipose tissue function". Experimental Physiology. 105 (8): 1201–1205. doi:10.1113/EP087877. PMC   8650997 . PMID   32144819.
  8. ↑ Kiepura A, Stachyra K, Olszanecki R (April 2021). "Anti-Atherosclerotic Potential of Free Fatty Acid Receptor 4 (FFAR4)". Biomedicines. 9 (5): 467. doi: 10.3390/biomedicines9050467 . PMC   8146529 . PMID   33923318.
  9. ↑ Wang HX, Liu C, Li YY, Cao Y, Zhao L, Zhao YJ, et al. (October 2023). "TUG-891 inhibits neuronal endoplasmic reticulum stress and pyroptosis activation and protects neurons in a mouse model of intraventricular hemorrhage". Neural Regeneration Research. 18 (10): 2278–2284. doi: 10.4103/1673-5374.369116 . PMC   10328290 . PMID   37056148.
  10. ↑ Ji G, Guo Q, Xue Q, Kong R, Wang S, Lei K, et al. (November 2021). "Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes". Molecules. 26 (22). Basel, Switzerland: 6907. doi: 10.3390/molecules26226907 . PMC   8624523 . PMID   34833999.
  11. ↑ Carullo G, Mazzotta S, Vega-Holm M, Iglesias-Guerra F, Vega-Pérez JM, Aiello F, et al. (April 2021). "GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery". Journal of Medicinal Chemistry. 64 (8): 4312–4332. doi:10.1021/acs.jmedchem.0c01002. PMC   8154576 . PMID   33843223.
  12. ↑ Wang X, Li X, Wei S, Wang M, Xu Y, Hu W, et al. (December 2022). "Discovery of Novel and Selective G-Protein Coupled Receptor 120 (GPR120) Agonists for the Treatment of Type 2 Diabetes Mellitus". Molecules. 27 (24). Basel, Switzerland: 9018. doi: 10.3390/molecules27249018 . PMC   9781217 . PMID   36558150.
  13. ↑ Li X, Zhang X, Xie X, Dong T, Lv C, Guan R, et al. (October 2024). "Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus". International Journal of Molecular Sciences. 25 (21): 11476. doi: 10.3390/ijms252111476 . PMC   11547093 . PMID   39519029.
  14. ↑ Jhinjharia D, Kaushik AC, Sahi S (January 2025). "A high-throughput structural dynamics approach for identification of potential agonists of FFAR4 for type 2 diabetes mellitus therapy". Journal of Biomolecular Structure & Dynamics. 43 (1): 176–196. doi:10.1080/07391102.2023.2280707. PMID   37978906.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.